enzon pharmaceuticals inc
(ENZN:NASDAQ GS)

Financial Statements for enzon pharmaceuticals inc (ENZN)

Currency in Millions of US Dollars	As of:	Dec 31 2009 Restated	Dec 31 2010 Reclassified	Dec 31 2011 Reclassified	Dec 31 2012	4 Year Trend
Revenues		51.4	54.2	42.4	41.6
TOTAL REVENUES		51.4	56.6	42.5	41.7
GROSS PROFIT		51.4	56.6	42.5	41.7
Selling General & Admin Expenses, Total		37.6	27.4	17.4	14.5
R&D Expenses		70.2	57.0	41.1	21.0
Other Operating Expenses		--	-0.4	-0.6	-0.9
OTHER OPERATING EXPENSES, TOTAL		107.8	84.1	57.9	34.6
OPERATING INCOME		-56.4	-27.4	-15.4	7.1
Interest Expense		-11.5	-6.3	-5.9	-5.3
Interest and Investment Income		4.3	3.5	1.7	2.6
Other Non-Operating Expenses, Total		0.2	42.1	5.1	-0.2
Other Non-Operating Income (Expenses)		0.2	42.1	5.1	-0.2
Merger & Restructuring Charges		-0.7	-14.0	-6.0	0.2
Gain (Loss) on Sale of Investments		--	-0.9	--	--
Other Unusual Items, Total		4.8	--	--	-11.3
EBT, INCLUDING UNUSUAL ITEMS		-59.3	-3.1	-20.6	-6.9
Income Tax Expense		-2.1	-0.3	0.2	-4.1
Earnings from Continuing Operations		-57.2	-2.8	-20.8	-2.8
EARNINGS FROM DISCOUNTINUED OPERATIONS		57.9	180.0	--	--
NET INCOME		0.7	177.2	-20.8	-2.8
NET INCOME TO COMMON INCLUDING EXTRA ITEMS		0.7	177.2	-20.8	-2.8
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS		-57.2	-2.8	-20.8	-2.8

Report Data Issue

To contact ENZON PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.